Syngenta signs long-term business agreement with Bayer CropScience

NewsGuard 100/100 Score

Syngenta and Bayer CropScience have entered into a long-term business agreement relating to a key plant biotechnology trait. Under the agreement, Syngenta has granted Bayer CropScience a worldwide, non-exclusive license for use of VIPCOT™ insect control technology in cotton.

The VIPCOT technology expresses two insecticidal proteins that are highly effective against a number of important cotton pests, including cotton bollworm (Helicoverpa zea) and tobacco budworm (Heliothis virescens). The addition of VIPCOT will complement Bayer's existing portfolio of cotton solutions, which includes high-performance cottonseed brands FiberMax®, Stoneville® and Surpass®, and technologies including LibertyLink® and GlyTol® herbicide-tolerance and TwinLink® insect resistance.

Davor Pisk, Chief Operating Officer of Syngenta Seeds, said, "This agreement further demonstrates the innovation that Syngenta is delivering in biotechnology. VIPCOT contains the same gene as AGRISURE VIPTERA™, to be launched by Syngenta in the US corn market later this year. The agreement with Bayer CropScience means that cotton growers will also see an expansion of the technology options available to them."

"Bayer is committed to being a leader in bringing innovative cotton solutions to farmers that help them tackle tough agronomic challenges and become more productive and profitable," said Dr. Joachim Schneider, Head of the BioScience business unit of Bayer CropScience. "We have one of the most robust cotton technology pipelines in the business, and we are pleased to be working with Syngenta to advance yet another insect control technology offering to benefit cotton farmers worldwide."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Azenta opens the doors to its new genomics laboratory in Oxford, UK